Sign in
Taking people in United StatesNo phase

Tests patients' own bone marrow cells for certain nerve and brain conditions

Tests own bone marrow cells in adults with nerve or brain conditions.

Key facts

Who runs it
MD Stem Cells
Where
Coral Springs and Westport, United StatesSee the 2 sitesAlso in 1 other country, 1 site
Trial code
Registry title
Neurologic Stem Cell Treatment Study
Status
Recruiting
People taking part
500 people, planned
Started
Jun 2016
Expected to end
31 Jul 2028
Type of study
Interventional
Treatments tested
  • Intravenous and Intranasal BMSC
Record updated
26 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with lasting damage to the nervous system who are unlikely to improve with standard care. It tests bone marrow stem cells given through a vein and the nose.

Age
Over 18 years
Sex
All sexes can join.
Disease stage
Documented functional damage to the central or peripheral nervous system, at least 6 months after the disease began, unlikely to improve with present standard of care.
Earlier treatment
People already on medical therapy (medicine or surgery) must be stable on it. The ongoing treatment must be unlikely to reverse the nerve damage.

Main reasons for not taking part

  • Cannot have a neurologic exam or cannot cooperate with it
  • Cannot or will not attend follow-up neurologic exams
  • Cannot give informed consent
  • Not medically stable, or at significant health risk from the procedure
  • Pregnant at the time of treatment

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care
  • Be at least 6 months post-onset of the disease
  • If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment
  • In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure
  • Be over the age of 18 and capable of providing informed consent
  • Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health

Who cannot take part

  • Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment
  • All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam
  • Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol
  • Patients must be capable of providing informed consent
  • In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function.
  • Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible

Where in United States

Also in 1 other country, 1 site

  • MD Stem CellsCoral Springs, United StatesContact: Steven Levy, MD, Study DirectorTaking people
  • MD Stem CellsWestport, United StatesContact: Steven Levy, MD, Study DirectorTaking people

About the trial

What the trial wants to find out

This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/

The group in the trial

  • Arm 1- Intravenous and Intranasal BMSCOther group

    Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously and intranasally (lower 1/3 of nasal passages).

    Treatment: Intravenous and Intranasal BMSC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Neurologic Bone Marrow Derived Stem Cell Treatment Study
Plain-language title
Tests patients' own bone marrow cells for certain nerve and brain conditionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 June 2026